27848-84-6
27848-84-6 結(jié)構(gòu)式
基本信息
麥角靈
尼麥角林
你先獲寧
麥角溴煙酯
麥角溴菸鹼酯
5-溴煙酸酯
尼麥角林EP雜質(zhì)J
麥角溴煙酯 EP標(biāo)準(zhǔn)品
尼麥角林NICERGOLINE
Memoq
fi6714
TA 079
Ergobel
CS-1354
Ergotop
Sermion
Cergodum
Dilasenil
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見(jiàn)問(wèn)題列表
未見(jiàn)嚴(yán)重不良反應(yīng)的報(bào)道，少數(shù)病人可有輕微不良反應(yīng)，一般為胃腸道不適（如胃痛）、面部潮紅、潮熱、頭暈、嗜睡、失眠、低血壓、耳鳴等。臨床試驗(yàn)可觀察到血液中尿酸濃度升高。
| Target | Value |
|
alpha-1A adrenergic receptor
() |
Nicergoline (0.3-30 μM; 24 h) attenuates activated microglia- and astrocytes-induced neuronal cell death.
Nicergoline (0.3-30 μM; 48 h) suppresses the production of proinflammatory cytokines and superoxide anion by activated microglia.
Nicergoline (10 mg/kg; i.v. once daily for 60 d) improves impaired neurogenesis and cognitive competence in mice with Alzheimer's disease.
Nicergoline (10 mg/kg; i.v. once daily for 60 d) inhibits apoptosis, inflammation and oxidative stress in hippocampal cells, and regulates the activity of hippocampal cells through the PI3K/AKT signaling pathway in mice.
| Animal Model: | 3×Tg-AD mice (male, 28-35 g, 6 weeks) with the Alzheimer's disease |
| Dosage: | 10 mg/kg |
| Administration: | I.v. once daily for 60 days |
| Result: |
Improved neurogenesis and cognitive competence.
Decreased the degree of dementia. Downregulated pathogenic Aβ-42 and -40 peptides and APP in the hippocampi. Increased Levels of the neuroprotective forkhead box protein P2 (Foxp2), Src homology 2-containing inositol phosphatase (SxIP) and end-binding proteins (EB) in the hippocampi. Exhibited marked differences in the dispersion of the pyramidal cell layer between the nicergoline-treated and control groups. |